GE Healthcare

Innovation in Breast Cancer detection and diagnosis doesn’t stop with the sanitary crisis.

It is challenging us to adapt our way of working and organizing.
Recognized experts in breast imaging will share their vision on how the latest progress could be used to adapt to this new normal.

Join a panel of experts who are shaping the horizon of Mammography
to listen, learn and debate on the future of your discipline.

The future of breast screening,
the impact of COVID-19 and the trend towards personalized screening
How contrast-enhanced mammography innovations can impact diagnosis?
The future role of AI in breast cancer detection


Friday 6th November • 2:00 pm Paris Time • Duration: 3 hours

Learn more about the topics that will be discussed
during the live and on our thought leaders

Session 1

Breast Imaging
in the (post)COVID era

2:00 pm - 3:15 pm

Breast Imaging – General Impact and Recovery from COVID-19 Pandemic
Pr. Francesco Sardanelli, MD (Italy)
Through the example of the crisis management in a major healthcare group, this presentation will focus on the impacts of COVID-19 on breast imaging departments and the lessons learned from the ongoing crisis.
COVID-19 Pandemic and CESM
Dr. Maxine Jochelson, MD (USA)
and Dr. Anat Kornecki, MD (Canada)
COVID-19 pandemic increases the risk to expose patients, breast imaging technologists and radiologists to infection. Two presentations will explore the possibility of using CESM to streamline breast imaging with a “single exam” approach by combining anatomic and vascular imaging in one appointment.
Personalized Screening - Dense Breasts
- The BRAID trial
Pr. Fiona Gilbert, MD, PhD (UK)
A few major studies are currently evaluating the efficiency of risk-based screening. This presentation will focus on screening women with dense breasts.
PANEL DISCUSSION: 3:15 pm - 3:30 pm
Session 2

Shaping the future of Breast Care embracing innovations

3:40 pm - 5:00 pm

CESM work-up after screening recalls – impact on biopsy rate
Dr. Simone Schiaffino, MD (Italy)
Could CESM reduce the unnecessary biopsies? An exciting question this study will try to answer.
CESM-guided biopsy – Clinical Experience
Dr. Corinne Balleyguier MD, PhD (France)
and Dr. Anat Kornecki, MD (Canada)
Two of the very first users of the technique will share their clinical experience: what’s the place and the potential of this new technique?
Artificial intelligence and breast cancer screening
Pr. Isabelle Thomassin-Naggara, MD, PhD (France)
After a review of the current status of AI in breast cancer screening, this presentation will question the implications and obstacles the use of AI raises in the scientific community, before discussing current AI research directions in breast imaging.
PANEL DISCUSSION: 5:00 pm - 5:15 pm